{"prompt": "['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '10.4.3.', 'Other Analyses', '73', '10.4.4.', 'Interim Analyses', '73', '10.4.5.', 'Exploratory Analyses', '74', '11. REFERENCES', '75', '12. APPENDICES', '78', '12.1.', 'Appendix 1: Abbreviations and Trademarks', '78', '12.2.', 'Appendix 2: Study Governance Considerations', '81', '12.3.', 'Appendix 3: Contraceptive Guidance and Collection of Pregnancy', 'Information', '85', '12.4.', 'Appendix 4: Liver Safety: Required Actions and Follow-up', 'Assessments', '88', '12.5.', 'Appendix 5: COPD Exacerbation Identification, Categorization and', 'Treatment Guidelines', '91', '12.5.1.', 'Guidelines for Identifying COPD Exacerbations', '91', '12.5.2.', 'COPD Exacerbation Severity', '92', '12.5.3.', 'Treatment of COPD Exacerbations', '92', '12.5.4.', 'Guidelines for Treatment with Corticosteroids', '92', '12.5.5.', 'Guidelines for Treatment with Antibiotics', '93', '12.5.6.', 'Onset and Resolution of COPD Exacerbations', '93', '12.5.7.', 'Guideline for assessing multiple mild exacerbations', '93', '12.5.8.', 'Guideline for assessing exacerbations that increase in', 'severity', '93', '12.6.', 'Appendix 6: Adverse Events: Definitions and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '94', '12.7.', 'Appendix 7: Medical Device Incidents: Definition and Procedures for', 'Recording, Evaluating, Follow-up, and Reporting', '100', '12.8.', 'Appendix 8: Clinical Laboratory Tests', '102', '12.9.', 'Appendix 9: Genetics', '104', '12.10. Appendix 10: Country-specific requirements', '105', '12.11. Appendix 11: Protocol Amendment History', '106', '9']['2017N323364_0', 'CONFIDENTIAL', '2019N398531_00', '207626', '1.', 'SYNOPSIS', 'Protocol Title: A Phase IV, 12 week, randomised, double-blind, double dummy study to', 'compare single inhaler triple therapy, fluticasone furoate/umeclidinium/vilanterol', '(FF/UMEC/VI), with tiotropium monotherapy based on lung function and symptoms in', 'participants with chronic obstructive pulmonary disease', 'Short Title: A randomised study, comparing FF/UMEC/VI single inhaler triple therapy', 'versus tiotropium monotherapy in participants with chronic obstructive pulmonary', 'disease', 'Rationale: Chronic obstructive pulmonary disease (COPD) guidelines advocate the use', 'of long-acting muscarinic receptor antagonists (LAMA) added to the combination of an', 'inhaled corticosteroid (ICS) plus a long-acting 2-adrenergic receptor agonists (LABA) as', 'second line therapy for the most advanced patients with significant symptoms and a high', 'risk of exacerbations. Regular treatment with ICS-containing regimens has been reported', 'to improve respiratory symptoms, lung function, health related quality of life (HRQoL)', 'and reduce the frequency of COPD exacerbations in patients with a forced expiratory', 'flow in 1 second (FEV1) <60 % predicted.', \"Population based studies of COPD treatment patterns demonstrate that 'open' triple\", 'therapy (use of ICS/LAMA/LABA delivered via multiple inhalers) is already widely used', 'in the real-life management of COPD. In 2011, 26 % of patients in the United States (US)', \"who were taking controller medicines for the treatment of COPD were taking an 'open'\", 'triple therapy, typically by adding fluticasone propionate/salmeterol (ICS/LABA) to', 'tiotropium (LAMA) or vice versa A study in the United Kingdom (UK) Clinical Practice', 'Research Database (CPRD) revealed that over a two-year period of time, 35% of COPD', 'patients initially prescribed a LAMA and 39 % initially prescribed an ICS/LABA stepped', \"up to an 'open' triple therapy regimen. In the four-year long-term safety study conducted\", 'with tiotropium, 46% of patients were receiving a concurrent fixed combination of', 'ICS/LABA in addition to tiotropium.', \"A number of studies have assessed the use of an 'open' triple therapy of fluticasone\", 'propionate/salmeterol or budesonide/formoterol (ICS/LABA) with tiotropium in', 'moderate-severe COPD patients. These studies have reported greater improvements in', 'lung function, HRQoL, hospitalization rates and rescue medication use, compared to dual', '(ICS/LABA) or LAMA alone, thus supporting the use of triple therapy in COPD. .These', 'studies have also shown that the number and type of reported adverse events (AE) were', 'generally similar with administration of dual or monotherapy doses for periods of up to', 'one year, and were mostly related to their pharmacological mode of action.', \"GlaxoSmithKline (GSK) is currently developing a once-daily 'closed' triple therapy of a\", 'ICS/LAMA/LABA combination [fluticasone furoate (FF)/umeclidinium', '(UMEC)/vilanterol (VI) (100/62.5/25 mcg)] in a single inhaler, with the aim of providing', 'a new treatment option for the management of symptomatic COPD patients at risk for', 'exacerbations which will reduce the exacerbation frequency, allow for a reduced burden', 'of polypharmacy, convenience, and increase the potential for improvement in lung', 'function, HRQoL and symptom control over established dual/monotherapies.', '10']\n\n###\n\n", "completion": "END"}